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Background: Particulate systems have received increasing attention for oral delivery of 
  biomolecules. The objective of the present study was to prepare submicron particulate 
  formulations of papain for pH-dependent site-specific release using pH-sensitive polymers.
Methods: Enteric submicron particle formulations of papain were prepared by w/o/w emulsion 
solvent evaporation using hydroxypropyl methylcellulose phthalate (HPMCP), Eudragit L100, 
and Eudragit S100, to avoid gastric inactivation of papain.
Results: Smaller internal and external aqueous phase volumes provided maximum encapsula-
tion efficiency (75.58%–82.35%), the smallest particle size (665.6–692.4 nm), and 25%–30% 
loss of enzyme activity. Release studies in 0.1 N HCl confirmed the gastroresistance of the 
formulations. The anionic submicron particles aggregated in 0.1 N HCl (ie, gastric pH 1.2) due 
to protonation of carboxylic groups in the enteric polymer. Aggregates , 500 µm size would not 
impede gastric emptying. However, at pH . 5.0 (duodenal pH), the submicron particles showed 
deaggregation due to restoration of surface charge. HPMCP submicron particles facilitated almost 
complete release of papain within 30 minutes at pH 6.0, while Eudragit L100 and Eudragit S100 
particles released 88.82% and 53.00% of papain at pH 6.8 and pH 7.4, respectively, according 
to the Korsmeyer–Peppas equation. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and fluorescence spectroscopy confirmed that the structural integrity of the enzyme was main-
tained during encapsulation. Fourier transform infrared spectroscopy revealed entrapment of 
the enzyme, with powder x-ray diffraction and differential scanning calorimetry indicating an 
amorphous character, and scanning electron microscopy showing that the submicron particles 
had a spherical shape.
Conclusion: In simulated gastrointestinal pH conditions, the HPMCP, Eudragit L100, and 
Eudragit S100 submicron particles showed good digestion of paneer and milk protein, and could 
serve as potential carriers for oral enzyme delivery. Stability studies indicated that formulations 
with approximately 6% overage would ensure a two-year shelf-life at room temperature.
Keywords: papain, hydroxypropyl methylcellulose phthalate, Eudragit L100, Eudragit S100, 
zeta potential
Introduction
Dietary proteins are essential for growth, repair, and regulation of homeostasis. 
  However, many people are intolerant of such foods, which includes baked beans, bean 
soup, soybean, and meat. This intolerance can lead to uncomfortable and embarrassing 
symptoms, such as flatulence, belching, diarrhea/constipation, malnutrition, food aller-
gies, anemia, undigested food in stool, chronic intestinal parasites, and abnormal flora. 
These symptoms usually occur during achlorhydria and/or pancreatin insufficiency.1,2 
Therefore, the need for a protein-digesting supplement arises.3 Nowadays, the demand International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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for digestive aids has increased, but the supply of pepsin (pre-
pared from hog mucosa) has decreased. Thus, plant-derived 
proteases like papain can be used because there is no scarcity 
of supply.4 Papain is a food-grade, highly active endolytic 
cysteine protease (EC 3.4.22.2) derived from Carica papaya. 
Its broad substrate specificity and ability to hydrolyze small 
peptides as well as large proteins make papain an ideal enzy-
matic supplement.5 However, the most critical challenge in 
oral delivery of papain is to preserve the formulation during 
its passage through the stomach without denaturation.6
The key to the success of digestive proteins as pharmaceu-
ticals is to have in place an efficient site-specific pH-dependent 
drug delivery system that allows the protein to gain access to 
the target site (intestine) at the right time and for an appropriate 
duration. pH-sensitive polymers (water-insoluble at low pH, 
water-soluble at high pH) are of particular interest because 
the drug release rate can be controlled by the pH of the envi-
ronment.7 The commonly used pH-sensitive enteric polymers 
are hydroxypropyl methylcellulose phthalate (HPMCP) and 
acrylic copolymers, ie, Eudragit L100 and Eudragit S100.8 
These polymers, when used as coating materials, produce 
films that are resistant to gastric fluid. HPMCP dissolves 
at a lower pH (5.0–5.5) than acrylic copolymers, and this 
solubility characteristic can be utilized for delivery of drug 
into the duodenum.9,10 Acrylic polymers, eg, Eudragit (Röhm 
Pharma, Darmstadt, Germany), a copolymer of methacrylic 
acid and its esters, have a special place in pH-dependent 
site-specific delivery of drugs.11 Eudragit L100 dissolves in 
the pH range of 6.0–6.5, which ensures drug release in the 
distal small intestine (ileum), while Eudragit S100 dissolves 
at pH . 7.0 and releases the drug into the colon. An enteric 
formulation of papain is more rational than immediate-release 
commercial papain products because the former would protect 
the acid-labile enzyme from gastric pH and deliver it to the 
site of action, ie, the small intestine.   Enteric-coated micro-
spheres of pancreatin 1.0–1.2 mm in diameter show 25% 
higher therapeutic effectiveness compared with 1.8–2.0 mm 
microspheres.12,13 Because microspheres with a size greater 
than 1.2 mm pass through the stomach at a slower rate than a 
meal, the same would be less efficacious in restoring enzyme 
activity than preparations with smaller sphere sizes.14 There-
fore, the design of particulate systems has received increasing 
attention for oral delivery of these biomolecules.15 The high 
surface area to volume ratios of nanospheres/submicron par-
ticles often cause a fast initial release, resulting in a high burst 
within a short duration.16,17 Nanospheres are well suited for 
target-specific drug delivery because of their small size,18,19 
and a relatively rapid release may be preferable for certain 
purposes, such as for delivery of digestive proteins. Thus, 
the objective of the present study was to prepare submicron 
particulate formulations of papain for pH-dependent site-
specific release using pH-sensitive polymers, ie, HPMCP, 
Eudragit L100, and Eudragit S100.
Materials and methods
Materials
HPMCP (molecular weight 45 kDa) and the methacrylic 
acid copolymers, Eudragit L100 and Eudragit S100 (average 
molecular weight 135 kDa), were gifted by Jubilant Organo-
sys, Noida, India. Potassium dihydrogen phosphate, sodium 
hydroxide, and hydrochloric acid (Qualigens Fine Chemicals, 
Mumbai, India), papain (source C. papaya), casein, tyrosine, 
and trichloroacetic acid (98.0%) were obtained from Himedia 
Laboratories Pvt Ltd, Mumbai, India, and were used as received. 
Disodium ethylenediamine tetra-acetate (99.5%), cysteine 
hydrochloride (99.0%), citric acid (98.0%), polyvinyl alcohol, 
and lactose were purchased from SD FineChem Ltd, Mumbai, 
India. A micro BCATM protein assay kit (Pierce, Rockford, 
IL) was obtained from ThermoScientific, Karnataka, India. 
Ethanol, dichloromethane, and isopropanol were obtained 
from Merck, Darmstadt, Germany. Saras paneer (a milk solid 
containing per 100.0 g: fat [24.0 g], protein [20.0 g], carbo-
hydrates [3.6 g], calcium [400.0 mg], phosphorus [200.0 mg], 
and vitamins B [0.05 mg] and A [120.0 µg]) and Saras toned 
milk were obtained from Jaipur Zila Dugdh Utpadak Sahakari 
Sangh Ltd, Rajasthan, India. All other chemicals and solvents 
were of analytical grade and used without further purification. 
Double-distilled water was used throughout the study.
Preparation of submicron particles
Papain-loaded submicron particles were prepared using a 
double-emulsion solvent evaporation technique. An aque-
ous solution of papain at a concentration of 141.06 mg/mL 
was prepared. The internal aqueous phase (W1, 0.4, 0.2, 0.1, 
0.05 mL, Table 1) containing papain, 3% v/v polysorbate 20 
(dispersing agent), and 0.16% w/v lactose as a cryoprotectant 
was emulsified with 5 mL of organic phase for one minute 
using an ultrasonic disruptor (30 W output power, 40% duty 
cycle, Branson Sonifier® 450, Danbury, CT). Temperature was 
maintained at 4°C, using an ice bath during   emulsification. 
The organic phase consisted of 200 mg of polymer (HPMCP, 
Eudragit L100, or Eudragit S100) in 5 mL of a mixed solvent 
system of dichloromethane, ethanol, and isopropanol in a ratio 
of 5:6:4.20 The resulting primary emulsion (W1/organic phase) 
was added drop by drop to the external aqueous phase (W2, 
50, 25, or 16 mL, Table 1) of 1% w/v polyvinyl alcohol and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 1 Different batches of SPs prepared with hPMcP, eudragit L 100 and eudragit S 100 polymer
Polymer Formulation code Volume of IAP (W1) mL W1:O Volume of EAP (W2) mL O:W2
hPMcP hS1 0.4 1:12.5 16 1:3.2
hS2 0.2 1:25 16 1:3.2
hS3 0.1 1:50 16 1:3.2
hS4 0.05 1:100 16 1:3.2
hS5 0.05 1:100 25 1:5
hS6 0.05 1:100 50 1:10
eudragit L 100 LS1 0.4 1:12.5 16 1:3.2
LS2 0.2 1:25 16 1:3.2
LS3 0.1 1:50 16 1:3.2
LS4 0.05 1:100 16 1:3.2
LS5 0.05 1:100 25 1:5
LS6 0.05 1:100 50 1:10
eudragit S 100 SS1 0.4 1:12.5 16 1:3.2
SS2 0.2 1:25 16 1:3.2
SS3 0.1 1:50 16 1:3.2
SS4 0.05 1:100 16 1:3.2
SS5 0.05 1:100 25 1:5
SS6 0.05 1:100 50 1:10
Abbreviations: SPs, Submicron particles; IAP, Internal aqueous phase; O, Organic phase; eAP, external aqueous phase; hPMcP, hydroxypropyl 
methylcellulose phthalate.
1.6% w/v lactose solution. The aqueous polyvinyl alcohol 
solution acted as an emulsion stabilizer. Emulsification was 
continued using an ultrasonic disruptor (30 W output power, 
40% duty cycle, Branson Sonifier) for two minutes to form 
a multiple emulsion (W1/organic phase/W2) at 4°C in an ice 
bath. The resulting W1/organic phase/W2 emulsion was stirred 
at room temperature for 16–18 hours with a magnetic stirrer to 
allow the solvent to evaporate. The submicron particles were 
collected and washed three times with distilled water by cen-
trifugation at 55,000 g for 25 minutes at 4°C. The submicron 
particles were resuspended in distilled water and lyophilized 
for 24 hours. The final product was stored in a desiccator at 
25°C. Different formulations prepared by varying the inter-
nal aqueous:organic:external aqueous phase ratio as well as 
polymer were coded as shown in Table 1. The optimized 
formulation prepared with 50 µL internal aqueous:5 mL 
organic:16 mL external aqueous phase (ie, HS4, LS4, SS4) 
was subjected to further investigation.
characterization of submicron particles
enzyme Assay
The proteolytic activity of papain was estimated using a modi-
fied casein digestion method (USP XXVII) in the presence 
of cysteine hydrochloride. An appropriately diluted standard 
papain solution in phosphate-cysteine disodium ethylenedi-
amine tetra-acetate buffer was added to 5 mL of buffered 1% 
casein substrate (pH 6.0 ± 0.1). After incubation at 37°C for 
20 minutes in a shaking water bath, the reaction was stopped 
by the addition of 3 mL of 30% w/v trichloroacetic acid 
  solution. The tubes were allowed to stand for 30–40 minutes 
at 40°C in a water bath to allow complete coagulation of the 
precipitated protein. Thereafter, the supernatant containing 
the digested amino acids was filtered through Whatman fil-
ter paper No 42 by discarding the first 3 mL of filtrate. The 
absorbance of the filtrate was measured at 280 nm using an 
ultraviolet-visible spectrophotometer (LabIndia® UV 3000+, 
Mumbai, India) against the standard plot of tyrosine absor-
bance versus tyrosine concentration (µg/mL). Papain activ-
ity was expressed in terms of casein digestion units (CDU). 
A CDU is the µg of tyrosine liberated per minute by 1 mg 
of enzyme under assay conditions.
Estimation of encapsulation efficiency
Ten milligrams of submicron particles were weighed accu-
rately and dissolved in 1 mL of phosphate buffer (pH 7.4). 
The resulting solution was analyzed for papain content by 
measuring absorbance in an enzyme-linked immunosor-
bent assay at 540 nm using a micro BCA protein assay 
kit for protein estimation. Results were expressed as the 
mean ± standard error of three experiments. Encapsulation 
efficiency was calculated as
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enteric nature of submicron particles
This test was performed to determine the extent of drug 
release in the acidic environment of the stomach (ie, pH 1–3). 
An accurately weighed sample (n = 3) of   papain-loaded 
HPMCP, Eudragit L100, or Eudragit S100 submicron parti-
cles equivalent to 10 mg of papain was introduced into 20 mL 
of 0.1 N HCl equilibrated at 37°C ± 0.5°C in a shaking water 
bath at 100 shakes per minute. Samples were withdrawn after 
120 minutes and the protein content was determined using a 
micro BCA protein assay kit.
In vitro drug release
In vitro release of papain from the enteric-coated submicron 
particles was recorded to determine the effect of pH on drug 
release. Accurately weighed samples (n = 3) equivalent to 
about 10 mg of papain were transferred to 20 mL of pre-
warmed dissolution media (pH 6.0, 6.8, or 7.4 phosphate 
buffer), maintained at 37°C ± 0.5°C in a shaking water bath 
at 100 shakes per minute. At predetermined time intervals, 
a 1 mL sample was withdrawn followed by replacement of 
the withdrawn volume by fresh phosphate buffer. Enzyme 
content was estimated using a micro BCA protein assay kit 
of protein estimation to confirm the integrity of the protein 
molecule. Results were expressed as the mean ± standard 
error of three experiments.
release kinetics
The mechanism of drug release was investigated by fitting 
the drug release data into zero order, first order, Higuchi, 
and Korsmeyer–Peppas equations. The goodness of fit of 
drug release was evaluated by the regression coefficient 
(R2) value.
Measurement of particle size  
and zeta potential
Freeze-dried submicron particles were dispersed in water 
after treatment in an ultrasonic disperser (Seishin Enterprise 
Co Ltd, Shibuya-Ku, Japan) for 20 seconds. The z average 
mean diameter, zeta potential, and polydispersity index 
of the papain-loaded submicron particles in an aqueous 
dispersion were measured by a dynamic light scattering 
method using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). Each value quoted was the average of 
determinations on three independent samples. Change in the 
behavior of submicron particles with a change in the pH, ie, 
pH 1.2–5.3 of the release media was analyzed using an   optical 
imaging system (Nikon Eclipse TS100, Nikon, Tokyo, 
Japan), equipped with a Sony camera (Hyper HAD model 
SSC-DC38DP, Elvetec, Templemars, France) and Optimas 
6.0 software (Media Cybernetics, Silver Spring, MD).
Digestion of paneer and milk protein
Paneer or a milk sample containing an amount equivalent 
to 450 mg casein was taken for determining the proteolytic 
activity of papain. Paneer 2.25 g passed through a sieve no 22 
or toned milk 17.14 mL was mixed with 20 mL of 0.1 N HCl 
and an optimized formulation of enteric submicron particles 
(HS4, LS4, or SS4) equivalent to 1.0 mg of papain was added 
and the mixture was maintained at 37°C ± 0.5°C in a shaking 
water bath at 100 shakes per minute for two hours followed 
by an increase in the pH to 6.0 by addition of disodium 
hydrogen phosphate and kept for two hours. Subsequently 
the pH was raised from pH 6.0 to 6.8 and kept for two hours, 
followed by a further increase in pH from pH 6.8 to 7.4 and 
maintained for two hours. At predetermined time intervals, a 
1 mL sample was withdrawn followed by replacement of the 
withdrawn volume by fresh phosphate   buffer. Samples were 
centrifuged at 17,000 rpm for 30 minutes and the superna-
tant was estimated for tyrosine content by a modified casein 
digestion method (USP XXVII).
SDS-PAge
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) of papain and optimized papain-loaded submi-
cron particles (HS4, LS4, and SS4) was performed according 
to the method of Laemmli on a slab gel containing 12% run-
ning gel and 5% stacking gel.21 Vertical minigel apparatus 
(Pharmacia, GE Healthcare, Uppsala, Sweden) was used to 
check for enzyme homogeneity. Samples of papain released 
from the submicron particles in phosphate buffer pH 7.4, 
papain (reference standard), and a molecular weight refer-
ence marker (molecular weight 14–94 kDa) were dissolved in 
sample buffer containing sodium dodecyl sulfate and a reduc-
ing agent (β-mercaptoethanol), loaded onto a vertical slab 
gel, and subjected to electrophoresis at 45 mA. Protein bands 
were fixed and stained with Coomassie Brilliant Blue R-250 
(0.1% w/v) in water:acetic acid:methanol (50:10:40).
Fluorescence spectroscopy
A fluorescence spectrometer (Cary Eclipse Fluorescence 
Spectrometer, Varian Australia Pty Ltd, Mulgrave, Australia) 
was used to detect changes in the tertiary structure of the 
papain-loaded submicron particles (HS4, LS4, and SS4). The 
emission spectrum (300–500 nm) of each sample was col-
lected at an excitation wavelength of 280 nm. When excited 
at 280 nm, the emission spectrum is a result of contributions International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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from both tryptophan and tyrosine residues in the protein.22 
Each protein spectrum was corrected by subtracting the 
spectrum of the appropriate blank solution (phosphate   buffer 
pH 7.4).
Fourier transform infrared spectroscopy
Fourier transform infrared spectra of papain, HPMCP, 
Eudragit L100, Eudragit S100, and papain-loaded HPMCP 
(HS4), Eudragit L100 (LS4), and Eudragit S100 (SS4) submi-
cron particles were obtained using a Fourier transform infra-
red spectrometer (FTIR-8400S, Shimadzu, Kyoto, Japan) as 
KBr pellets in the range of 4000–400 cm−1.
Powder x-ray diffraction
The x-ray diffraction patterns for papain, HPMCP, Eudragit 
L100, Eudragit S100, and papain-loaded HPMCP (HS4), 
Eudragit L100 (LS4), and Eudragit S100 (SS4) submicron 
particles were recorded using a x-ray diffractometer (Siemens, 
Model D5000, Munich, Germany) using CuKα1 radiation of 
wavelength 1.5406 Å, generated at 45 kV , 40 mA, by measur-
ing the angle of diffraction over the range of 3.0°–45.0° 2θ.
Differential scanning calorimetry
The thermal characteristics of papain powder, HPMCP, 
Eudragit L100, Eudragit S100, and papain-loaded HPMCP 
(HS4), Eudragit L100 (LS4), and Eudragit S100 (SS4) submi-
cron particles were determined using a differential scanning 
calorimeter (DSC-60, Shimadzu). Samples were crimped in 
a standard aluminum pan and heated from 40°C to 250°C 
at a heating rate 10°C per minute under constant purging of 
nitrogen at 30 mL/min.
Scanning electron microscopy
Particle morphology was analyzed by scanning electron 
microscopy (LEO 435 VP) using an acceleration voltage of 
2 kV . The surface microscopic structure of the submicron par-
ticles was also investigated. Particles were mounted on brass 
stubs using carbon paste. Scanning electron micrographs were 
taken using variable pressure scanning electron microscopy 
at the required magnification and room temperature.
Stability testing
Accurately weighed parent papain bulk or selected submicron 
particles (HS4, LS4, and SS4) equivalent to 10 mg of papain 
were filled into hard gelatin capsules (size 3). The capsules 
were packed in amber-colored glass bottles and subjected 
to stability testing according to the International Confer-
ence on Harmonization guidelines for zones III and IV. 
The containers packed with prepared capsules of papain 
parent bulk or submicron particles were kept for accelerated 
(40°C ± 2°C/75% ± 5% relative humidity) and long-term 
(30°C ± 2°C/65% ± 5% relative humidity) stability for six 
months and 12 months, respectively. Samples kept under 
accelerated storage conditions were withdrawn at months 0, 
1.5, 3, and 6, and papain activity was estimated. Similarly, 
samples stored at 30°C ± 2°C/65% ± 5% relative humidity 
were withdrawn at months 0, 3, 6, 9, and 12, and analyzed 
for papain activity. Visual inspection of samples for discol-
oration of capsule content was also done after completion 
of the stability study.
Results and discussion
Formulation variables
The effect of the formulation variables on yield, encap-
sulation efficiency, and size of HPMCP, Eudragit L100, 
and Eudragit S100 submicron particles prepared by this 
double emulsion solvent evaporation technique is shown in 
Table 2. With respect to the total amount of papain used for 
preparation, submicron particles made with Eudragit L100 
and Eudragit S100 encapsulated a larger amount of papain 
compared with HPMCP (Table 2). This could be due to a 
difference in the molecular weight of the polymers. Low 
molecular weight polymers incorporate a smaller amount of 
protein than those of higher molecular weight.23,24
The type of polymer and volume of the internal aqueous 
phase affected the encapsulation efficiency of the papain-
loaded submicron particles. It was observed that as the volume 
of internal aqueous phase decreased from 0.4 mL to 0.05 mL, 
the encapsulation efficiency increased and particle size 
decreased for all the polymeric particles, although the extent 
varied slightly. The mean diameter of the submicron particles 
varied from 665.6 ± 34 nm to 2785.6 ± 45 nm with varying 
internal aqueous phase volume from 50 µL to 400 µL for all 
three polymers used in the study. Use of a 50 µL internal aque-
ous phase provided the highest papain-loading efficiency and 
the smallest particle size for HPMCP (75.58% ± 4.03% and 
665.6 ± 34 nm, respectively), Eudragit L100 (81.17% ± 2.88% 
and 692.4 ± 62 nm), and Eudragit S100 (82.35% ± 3.10% and 
676.4 ± 66 nm) submicron particles (Table 2).
It has been reported that the droplet size of a primary 
emulsion may increase with an increase in the volume of 
the internal phase which, in turn, may be responsible for the 
increase in size of particles.25,26 Accordingly, during forma-
tion of a primary emulsion, sonication of a small volume 
leads to smaller droplet formation, which could account 
for a smaller particle size. A higher rate of leaching, poor International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  physical stability of the primary emulsion, and an increase in 
the number of pores on the surface of the nanospheres may 
be responsible for the decrease in encapsulation efficiency 
associated with the increase in volume of the internal phase 
of the primary emulsion.27,28 Thus, a smaller volume of the 
internal aqueous phase is desirable for higher encapsula-
tion of papain and particles of smaller size. This improved 
encapsulation efficiency may be simply due to a relatively 
greater proportion of polymer with respect to the amount 
of enzyme. The amount of polymer in the organic phase 
is constant but the volume of the internal aqueous phase is 
variable. Therefore, there is a relative increase in the polymer 
load with a decrease in the volume of the internal aqueous 
phase. The increase in polymer load leads to a shorter time 
for the composition of the polymer solution to reach the 
viscous (gelation) boundary, resulting in rapid formation 
of a film-like membrane on the periphery of the droplets. If 
the film-like polymeric membrane is quickly solidified, the 
microparticle structure is more fixed and thus solvent and 
nonsolvent counter diffusion is delayed. As a consequence, 
less water may be able to diffuse into the dispersed phase 
and less drug (or enzyme) will be carried by the solvent into 
the aqueous phase.29 A polydispersity index (Table 2) of 
submicron particles in the range of 0.15–0.3 indicates reason-
able size homogeneity, while a polydispersity index . 0.3 
indicates heterogeneity.30 The optimized ratio of the internal 
aqueous phase to organic phase was 1:100, ie, 50 µL of 
internal aqueous phase and 5 mL of organic phase.
The effect of a change in volume of the external aqueous 
phase on encapsulation efficiency of the particles was also 
studied. As the volume of external aqueous phase was 
increased from 16 mL to 50 mL, the encapsulation efficiency 
decreased and particle size increased (Table 2). Thus, for 
maximum encapsulation, the optimized ratio of the internal 
aqueous (W1):organic:external aqueous (W2) phases was 
1:100:320 (ie, 50 µL internal aqueous phase to 5 mL organic 
phase to 16 mL of external aqueous phase).
Jain et al31,32 encapsulated porcine insulin in Eudragit 
L100 and Eudragit S100 microspheres using a w/o/w emul-
sion solvent evaporation and observed actual drug loading 
of 0.45% and 0.43% and an encapsulation efficiency of 
84.5% and 81.8%, respectively. In the present experiment, 
the actual drug loading of papain in the Eudragit L100 and 
Eudragit S100 submicron particles was 2.76% and 2.80%, 
respectively, and the corresponding encapsulation efficiency 
was 81.17% and 82.35%. The higher drug loading observed 
in the present study appears to be due to use of a higher con-
centration of papain in the internal aqueous phase compared 
with insulin (141.06 mg/mL of papain against 32 mg/mL 
of insulin). The yield of submicron particles obtained from 
the different batches of polymers varied from 49.66% to 
58.16%, irrespective of enzyme loading. The low yield of 
submicron particles could be attributable to losses occur-
ring during various steps of processing, such as adherence 
of the polymeric solution to the glass container and loss of 
submicron particles during the washing step. Loss due to 
Table 2 Effect of formulation variables on yield, encapsulation efficiency and particle size of HPMCP, Eudragit L 100 and Eudragit S 100 
SPs prepared by double emulsion solvent evaporation technique
Formulation  
code
Yield (%)  
(mean ± SE)
Theoretical  
loading (%)
Actual  
loading (%)
Encapsulation efficiency  
(mean ± SE) (%)
Particle size  
(mean ± SE) nm
Poly dispersity   
index
hS1 49.66 ± 2.60 21.95 2.71 ± 0.39 12.34 ± 1.77 2725.1 ± 32 0.678
hS2 51.88 ± 1.53 12.34 2.80 ± 0.40 22.69 ± 3.25 1281.8 ± 28 0.519
hS3 52.55 ± 3.27   6.58 2.74 ± 0.30 41.64 ± 4.62   915.6 ± 48 0.568
hS4 54.05 ± 3.17   3.40 2.57 ± 0.14 75.58 ± 4.03   665.6 ± 34 0.221
hS5 54.00 ± 3.21   3.40 2.41± 0.10 70.88 ± 3.05   708.3 ± 31 0.365
hS6 56.55 ± 1.94   3.40 2.31 ± 0.12 67.94 ± 3.57   787.1 ± 35 0.269
LS1 50.13 ± 4.11 21.95 3.15 ± 0.23 14.35 ± 1.06 2476.7 ± 36 0.667
LS2 54.51 ± 4.87 12.34 3.17 ± 0.17 25.68 ± 1.36 1721.4 ± 56 0.723
LS3 50.46 ± 3.67   6.58 2.99 ± 0.26 45.44 ± 3.99 1075.3 ± 45 0.476
LS4 56.56 ± 4.61   3.40 2.76 ± 0.10 81.17 ± 2.88   692.4 ± 62 0.225
LS5 52.52 ± 2.37   3.40 2.69 ± 0.14 79.11 ± 4.04   710.3 ± 24 0.373
LS6 57.22 ± 3.81   3.40 2.57 ± 0.15 75.58 ± 4.45   801.2 ± 73 0.559
SS1 51.23 ± 4.27 21.95 3.14 ± 0.27 14.30 ± 1.22 2785.6 ± 45 0.618
SS2 58.16 ± 4.16 12.34 3.14 ± 26 25.44 ± 2.15 1705.2 ± 24 0.755
SS3 55.08 ± 3.67   6.58 2.93 ± 0.20 44.52 ± 3.02 1097.4 ± 58 0.305
SS4 53.16 ± 4.16   3.40 2.80 ± 0.11 82.35 ± 3.10   676.4 ± 66 0.282
SS5 54.12 ± 2.57   3.40 2.70 ± 0.12 79.41 ± 3.57   747.2 ± 23 0.670
SS6 53.31 ± 2.34   3.40 2.58 ± 0.13 75.88 ± 3.68   801.8 ± 20 0.762International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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adherence could be minimized by using apparatus made of 
plastic or polyethylene.
During preparation of the submicron particles, the papain 
activity decreased from 887.92 CDU to 672.08 CDU, 628.75 
CDU, and 644.58 CDU for HPMCP, Eudragit L100, and 
Eudragit S100 particles, respectively. A loss of enzyme 
activity of about 25%–30% was observed under the condi-
tions of the experiment for optimized formulations of the 
three different polymers. This might be due to the denatur-
ing effect of the mixed organic solvent system, mechanical 
stress exerted by the probe during sonication, and exposure 
to vacuum during lyophilization.
enteric nature of submicron particles
Studies of the optimized formulations revealed that release 
of papain from the papain-loaded submicron particles was 
mainly influenced by the nature of the polymer, as well as the 
pH of the surrounding media. Complete enteric coating could 
not be achieved because 8.39%, 6.01%, and 7.75% of papain 
was released from HPMCP (HS4), Eudragit L100 (LS4), 
and Eudragit S100 (SS4) particles, respectively, in 0.1 N 
HCl (pH 1.2) in two hours. The release of enzyme from the 
submicron particles in acidic medium could be due to insuf-
ficient coating or film defects created during   lyophilization. 
Since the polymers are insoluble in the release media of pH 
1.2, the particles were only slightly swollen and remained 
intact in this case. Studies in which papain was immobilized 
in ionotropically crosslinked kappa-carrageenan and sodium 
alginate gel beads reported release of 90% of papain from the 
formulation within 50 minutes in simulated gastric fluid.33,34 
As a result, papain would remain almost inactive as well as 
lose its structural integrity at low pH in the stomach (pH 1.2). 
Hence, an adequate amount of papain would not reach the 
target site (intestine) for digestion of proteins. Thus, use of 
an enteric polymer matrix system for oral delivery of papain 
would be satisfactory (because the enzyme is not released 
from the optimized formulation in a significant amount in 
the stomach) for maintaining the structural integrity of the 
enzyme during transit through the stomach.
The submicron particles had a negative charge contrib-
uted by the carboxylic groups of phthalic acid (pKa about 
4.47) and methacrylic acid (pKa about 4.23) residues in the 
enteric polymer backbone. The zeta potentials of the aque-
ous dispersion of formulations HS4, LS4, and SS4 were found 
to be −25.14, −27.33, and −28.27 mV , respectively. It was 
observed that the zeta potential of HS4, LS4, and SS4 particles 
was changed in 0.1 N HCl to 0.3051, 0.1154, and 0.2682 mV , 
respectively. Optical microscopy showed aggregation of the 
particles in 0.1 N HCl (pH 1.2, Figure 1). We know that the 
carboxylic groups of anionic particles become protonated if 
the pH is below the pKa of the carboxylic acid, leading to 
a decrease in the surface charge of the particles. Reduction 
in surface charge diminishes electrostatic repulsion and 
increases the Van der Waals forces between the particles, 
facilitating aggregation.35 Thus, it appears quite natural that 
the submicron particles would aggregate in 0.1 N HCl which 
has a pH 1.2 below the pKa of phthalic acid (pKa about 
4.47) and methacrylic acid (pKa about 4.23).36 Addition of 
0.5% soybean oil did not have any appreciable effect on the 
zeta potential in 0.1 N HCl or on aggregation. It has been 
reported that the stomach retains food particles until these are 
fragmented into particles smaller than 0.5 mm in diameter.37 
Since the size of aggregated submicron particles was less than 
500 µm, there should not be any significant delay in gastric 
emptying of the particles. Subsequent to gastric emptying, the 
particles would enter the duodenum where the pH is . 5.0. 
Accordingly, as the pH of the dispersion of submicron 
particles in 0.1 N HCl was raised to 5.3, deaggregation of 
particles was observed due to pH-induced deprotonation of 
carboxylic groups and restoration of negative charge. The 
result suggests that the particles, on being emptied by the 
stomach into the duodenum, which has a pH . 5.0, would 
undergo deaggregation, resulting in an increase in the effec-
tive surface area of the particles.
ABC
100 µm 100 µm 100 µm
Figure 1 effect of ph 1.2 on the aggregation of optimized papain loaded enteric SPs of hPMcP (A), eudragit L 100 (B) and eudragit S 100 (C).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In vitro release profile
In vitro drug release from all the optimized batches of 
submicron particles showed 6.01%–8.39% of drug release 
in 0.1 N HCl (pH 1.2) in two hours. Next, the drug release 
was studied at pH 6.0, 6.8, and 7.4 for the HPMCP, Eudragit 
L100, and Eudragit S100 particles, respectively. HPMCP 
particles showed almost complete drug release in half an hour 
at all pHs studied, whereas Eudragit L100 particles showed 
20.71% and 88.82% drug release at pH 6.0 and 6.8, respec-
tively, during the same time interval (Figure 2). Eudragit 
S100 particles showed only 13.01%–15.23% drug release at 
pH 6.0 and 6.8 compared with 53.00% release at pH 7.4 in 
30 minutes. However, complete release of drug from LS4 and 
SS4 particles at pH 6.8 and 7.4 was obtained in 40 minutes 
and 70 minutes, respectively. The drug release from these 
particles is consistent with the pH-dependent solubility of 
the polymers, because HPMCP dissolves at a pH of around 
5.0–5.5, while Eudragit L100 and Eudragit S100 dissolve at 
pH . 6.0 and pH . 7.0, respectively.38
release kinetics
The enzyme release data show a good fit to the Korsmeyer–
Peppas equation, which can be confirmed by comparing 
the values for the regression coefficient of the zero order 
(R0
2 = 0.944, 0.967, and 0.969 for HS4, LS4, and SS4), 
first order (R1
2 = 0.893, 0.887, and 0.946), Higuchi matrix 
(R2 = 0.990, 0.993, and 0.971) and Korsmeyer–Peppas 
(Rk
2 = 0.993, 0.995, and 0.979) equations. The value of n 
(0.43, n ,0.85), ie, the diffusion exponent of the Korsmeyer–
Peppas equation, indicates that the release of papain from 
HS4, LS4, and SS4 particles is anomalous, ie, contributed to 
by a combination of dissolution and diffusion. The release 
mechanism of dissolution and diffusion from anionic 
polymers (HPMCP, Eudragit L100, and Eudragit S100) is 
pH-dependent.39
Digestion of paneer and milk protein
Milk and paneer are the most common sources of dietary pro-
tein consumed on the Indian subcontinent. Thus, assuming the 
maximum gastrointestinal transit time through the absorptive 
areas of the gastrointestinal tract to be 12 hours,40 the ability of 
the HS4, LS4 and SS4 formulations to digest paneer and milk 
protein was evaluated in progressive pH media simulating 
gastrointestinal pH conditions. The substrate (milk or paneer) 
was successively exposed to the submicron particles at pH 
1.2 for two hours, pH 6.0 for two hours, pH 6.8 for two hours, 
and pH 7.4 for two hours. It was observed that 8.61 ± 4.56 mg 
and 0.23 ± 4.23 mg of tyrosine was formed from paneer with 
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Figure 2 effect of ph on the release of enzyme from the optimized formulation of papain loaded SPs of hPMcP (hS4), eudragit L 100 (LS4) and eudragit S 100 (SS4) at ph 
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HS4 and LS4 at pH 6.0 after two hours, whereas 8.72 ± 3.92 mg 
and 0.42 ± 3.42 mg of tyrosine was formed from milk. Subse-
quently, as the pH was raised to 6.8, the total amount of tyrosine 
formed from paneer was 8.64 ± 3.68 mg, 8.88 ± 4.16 mg, and 
0.12 ± 3.17 mg with HS4, LS4, and SS4 in two hours while 
8.69 ± 4.52 mg, 8.77 ± 4.66 mg, and 0.17 ± 4.53 mg of tyrosine 
was formed from milk. With a further increase in pH from 
6.8 to 7.4, the total amount of tyrosine formed from paneer 
was 8.64 ± 3.22 mg, 8.91 ± 3.94 mg, and 8.03 ± 3.45 mg with 
HS4, LS4, and SS4, respectively, after two hours, whereas the 
corresponding tyrosine formed from milk was 8.71 ± 3.98 mg, 
8.98 ± 3.64 mg, and 8.24 ± 4.28 mg. Thus, HPMCP and 
Eudragit L100 particles would have good digestive power 
for protein/peptides at pH 6.0 and 6.8, respectively, during 
a short gastro-small intestinal transit time of 4–6 hours,41 
whereas Eudragit S100 particles would take longer to digest. 
This indicates that in an in vivo situation, as the submicron 
particles pass through the stomach to the intestine, uniform 
mixing of the submicron particles with chyme would facilitate 
digestion of proteins.
SDS-PAge
SDS-PAGE analysis of both papain and papain released from 
the HS4, LS4, and SS4 particles demonstrated that neither pro-
tein fragmentation nor covalent dimerization occurred during 
the encapsulation process (Figure 3). There were no additional 
bands to indicate the presence of aggregates (molecular 
weight . 23 kDa) or other fragments produced by hydrolysis 
of enzyme proteins (molecular weight , 23 kDa). Hence, the 
data suggest that the structural integrity (ie, primary structure) 
of papain was not significantly affected during the entrapment 
procedure (and in potentially harsh conditions, such as contact 
with organic solvents and mechanical agitation).
Fluorescence spectroscopy
The fluorescence spectra of papain and papain released from 
the HS4, LS4, and SS4 particles are compared in Figure 4. 
The λmax of the nonentrapped papain spectrum was 332 nm. 
1
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Figure 3 SDS-Pege analysis of papain samples. Lane 1: molecular weight markers 
(14-94kDa); lane 2: papain (reference standard); lane 3, 4 and 5: papain released from 
optimized formulations of papain loaded hPMcP, eudragit L 100 and eudragit S 100 
SPs respectively.
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Figure 4 Intrinsic fluorescence spectra of papain (reference standard) and papain released from optimized formulations of papain loaded HPMCP, Eudragit L 100 and Eudragit 
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Papain released from the HS4, LS4, and SS4 particles showed 
a slight shift in λmax to longer wavelengths. However, λmax was 
within the acceptable range of 300–350 nm, corresponding 
to the intense emission of tryptophan.42 Thus, the HS4, LS4, 
and SS4 particles maintained the tertiary structure of papain 
under encapsulated conditions.
Fourier transform infrared spectroscopy
The Fourier transform infrared spectra of papain, Eudragit 
L100, Eudragit S100, HPMCP, papain-loaded Eudragit L100 
(LS4), Eudragit S100 (SS4), and HPMCP (HS4) particles are 
shown in Figure 5. The Eudragit L100 and Eudragit S100 
polymers contain both carboxylic acid and ester groups. 
4000
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Figure 5 The FTIr spectra eudragit L 100, eudragit S 100, hPMcP, papain powder and optimized formulation of papain loaded hPMcP, eudragit L 100 and eudragit S 100 SPs.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The spectra of Eudragit L100 and Eudragit S100 show the 
carbonyl vibrations of the ester group at around 1728 cm−1. 
The HPMCP polymer shows a broad band in the region 
of 3500–3250 cm−1, having a peak at 3438 cm−1 due to a 
polyhydroxyl (−OH)n group and an ester C=O stretching at 
1735.3 cm−1. Papain also showed one predominant band at 
3450–3225 cm−1, having a peak at 3300 cm−1 due to the N–H 
stretch of a secondary N–substituted amide, p-substituted 
aromatic out of plane C–H deformation of an aromatic resi-
due of tryptophan or tyrosine at 868 cm−1 and 850 cm−1, with 
C=O stretch of a carboxylate anion and an amide group at 
1654.2 cm−1, and strong peaks between 1150–1050 cm−1 and 
705–570 cm−1 due to C–S stretch of sulfides and disulfides. 
The spectra of the papain-loaded enteric submicron polymer 
particles showed peaks at 3386.2 cm−1 for the substituted sec-
ondary amide, 875 cm−1 due to the substituted aromatic ring, 
and 1145 cm−1 and 600 cm−1 due to C–S stretch of sulfides 
and disulfides, suggesting entrapment of the enzyme.
Powder x-ray diffraction
Figure 6 shows the powder diffraction patterns for papain, 
HPMCP, Eudragit L100, Eudragit S100, and optimized 
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Figure 6 XrD pattern of eudragit S 100, eudragit L 100, hPMcP, papain powder and optimized formulation of papain loaded hPMcP, eudragit L 100 and eudragit S 100 SPs.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 7 The DSc thermograms of eudragit S 100, eudragit L 100, hPMcP, papain powder and optimized formulations of papain loaded eudragit S 100, eudragit L 100 and 
hPMcP SPs.
papain-loaded submicron particles of HPMCP, Eudragit 
L100, and Eudragit S100. The diffractograms of papain 
and the polymers indicated an amorphous structure. The 
diffractograms for the submicron particles also indicated an 
amorphous structure, and those for the submicron particles 
appeared identical to the HPMCP, Eudragit L100, and 
Eudragit S100 polymers.
Differential scanning calorimetry
The differential scanning calorimetry thermograms of 
papain, HPMCP, Eudragit L100, Eudragit S100 and opti-
mized papain-loaded submicron particles of HPMCP (HS4), 
Eudragit L100 (LS4), and Eudragit S100 (SS4) are shown in 
Figure 7. Papain showed two endothermic peaks at 74.49°C 
and 174.47°C. Eudragit L100 and Eudragit S100 showed International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 8 SeM micrographs of optimised formulations of papain loaded hPMcP (A), eudragit L 100 (B) and eudragit S 100 SPs (C).
a broad endotherm with a peak at 216.2°C and 188.51°C, 
respectively, while HPMCP exhibited two broad endotherms 
at 198.75°C and 211.57°C, which are typical of amorphous 
material. Differential scanning calorimetry thermograms of 
papain-loaded submicron polymeric particles were similar 
to the thermograms of the respective polymers, but the 
polymeric peaks were shifted to lower temperatures because 
papain was present as an impurity (2.57%–2.80%). However, 
the thermograms did not show any melting peak analogous 
to papain. Maghsoodi43 prepared naproxen-loaded micropar-
ticles with Eudragit L100. Differential scanning calorimetry 
thermograms of these microparticles revealed that the melting 
peak of naproxen disappeared gradually with an increasing 
ratio of Eudragit L100 to drug in the   formulation. When the 
ratio of Eudragit L100 to drug was 4:1, no melting peak of 
drug was observed. The results suggest that naproxen had 
been highly dispersed in the microparticles at a 4:1 polymer/
drug ratio, similar to an amorphous state. This was sup-
ported by x-ray analysis data in which no crystalline peak of 
naproxen was found in the microparticles at a 4:1 polymer/
drug ratio. In view of the aforegoing discussion, it appears 
quite likely that the differential scanning calorimetry thermo-
gram for papain-loaded submicron particles which contained 
2.57%–2.80% of drug, (ie, the drug is present as an impurity 
in the polymer) also would not show any melting peak of 
papain, because the enzyme is dispersed in an amorphous 
state in an amorphous polymer. Powder x-ray diffraction for 
the papain-loaded submicron particles also did not show any 
peak for papain. Thus, the results of the present study are in 
accordance with already published results.
Particle morphology
Particles were analyzed by scanning electron microscopy to 
observe the morphology of the submicron particles. The particles 
made of Eudragit L100, Eudragit S100, and HPMCP containing 
papain were spherical and had smooth surfaces (Figure 8).
Stability study
Tables 3 and 4 show the results of the accelerated and long-
term stability studies of the submicron particles and free 
papain formulations. The submicron particle formulations of 
HS4, LS4, and SS4 showed around 92% papain content on stor-
age under accelerated conditions (ie, 40°C and 75% relative 
humidity) for six months, while the free papain formulation 
showed a 73% drug content (Table 3).   However, HS4, LS4, 
and SS4, showed around 92% drug content when stored at 
30°C/65% relative humidity for 12 months against a 72.55% 
drug content for the free papain formulation. The results sug-
gest improved stability of the enzyme on entrapment in poly-
mer. On the basis of first order rate constants, the calculated 
t90 of LS4, SS4, and HS4 at 30°C and 65% relative humidity 
would be 495, 474, and 460 days,   respectively (Table 4).   
Table 3 Stability of free papain and optimised formulations of papain (hS4, LS4 and SS4) under accelerated storage conditions (40°c ± 
2°c/75% ± 5% rh)
Formulation code % Papain activity remaining Kcalc (day)-1
0 M 1.5 M 3 M 6 M
Papain 100.00 ± 2.26 91.93 ± 3.20 82.78 ± 3.19 73.58 ± 2.46 1.71 × 10−3
hS4 100.00 ± 4.19 97.86 ± 3.13 95.30 ± 5.49 92.09 ± 3.12 4.58 × 10−4
LS4 100.00 ± 3.77 97.86 ± 3.58 95.79 ± 3.21 92.62 ± 2.39 4.26 × 10−4
SS4 100.00 ± 3.11 97.37 ± 3.65 94.88 ± 2.19 92.13 ± 1.98 4.55 × 10−4
Note: *Values are mean ± Se (n = 3).
Abbreviations: M, months; Kcalc, calculated first-order degradation rate constant.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The Kcalc/t90 values suggest that optimized formulations will 
not ensure a two-year shelf life (t90) for the product and might 
need some overages, resulting in a need for a higher initial 
drug concentration. Thus, to ensure a two-year shelf-life, the 
HS4, LS4, and SS4 formulations would need 4.91%–6.14% 
overage (Table 4). The color of bulk papain powder, ie, non-
entrapped papain, changed from pale buff to light brown. In 
contrast, the papain-loaded submicron particle formulations 
did not show any color change. Thus, the stability of papain 
entrapped in submicron particles was significantly improved 
in comparison with the bulk papain powder.
Conclusion
Papain was successfully encapsulated in enteric submicron 
particles by double emulsion solvent evaporation, optimiz-
ing the various formulation parameters in order to attain 
maximum encapsulation efficiency and a spherical shape, 
with an almost monodispersed particle size distribution and 
an optimum in vitro release profile. The release profiles for 
the formulations confirmed their gastroresistance, thus allow-
ing pH-dependent release of papain in the gastrointestinal 
tract. Eudragit L100 and HPMCP particles disintegrated and 
showed complete release of papain in the pH environment of 
the small intestine within four hours, whereas Eudragit S100 
needs higher pH and a longer time for drug release. Thus, 
HPMCP, Eudragit L100, and Eudragit S100 particles have 
great potential as oral carriers for delivery of papain to the 
small and large intestines to facilitate digestion of proteins.
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